Here are the 8-K filings from Vivos Inc (RDGL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow RDGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RDGL filings page.
Vivos Inc. entered into a stock purchase and exchange agreement with Carl Cadwell, a member of its Board of Directors, on October 7, 2026. Cadwell agreed to purchase 250,000 Series D Convertible Preferred Stock shares for a purchase price of $250,000 and exchange 385,302 Series C shares for 385,302 Series D shares; the share exchange was consummated that day.
After the transaction, Vivos reported 635,302 Series D shares outstanding, with a conversion price of $.08 per share, and no Series C shares outstanding. On October 8, 2026, Vivos filed a Certificate of Elimination for Series C, effective that date; the board had approved the filing. The Series D shares issued under the agreement were described as exempt from Securities Act registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.
On September 28, 2026, VIVOS INC. designated 1.0 million of its 10.0 million authorized preferred shares as Series D Convertible Preferred Stock. Each Series D share has a $1.00 stated value and a $1.00 liquidation preference, ranks senior to Common Stock and equity securities ranking junior to it, and may be converted at the holder’s election into common shares equal to the stated value divided by $0.08, subject to adjustment under the designation.
Series D holders vote with Common Stock holders, with the equivalent of 50 votes for each common share issuable upon conversion. Conversion rights are limited if a holder’s beneficial ownership would exceed 4.99% immediately after conversion; the limit may be 9.99% after 61 days’ prior written notice to VIVOS.
Vivos Inc. filed an amended current report to correct typographical errors related to its description of a leadership appointment, while confirming two key executive changes. The company appointed Brad Allan Weeks as President under an employment agreement effective September 1, 2025 through December 31, 2027. His compensation includes an annual base salary of $192,000, a monthly grant of $3,000 in shares of common stock issued at the end of each fiscal quarter based on the quarter-end closing price, plus customary benefits and expense reimbursement.
David J. Swanberg was appointed Chief Operating Officer under an executive consulting agreement effective September 1, 2025 through December 31, 2028. He will receive consulting compensation of $12,000 per month and a monthly grant of $3,000 in common stock, also determined at each fiscal quarter end closing price, along with customary covenants such as confidentiality, non-competition and non-solicitation. Both agreements are filed as exhibits and there are no disclosed related party arrangements beyond these terms.
Vivos Inc. appointed Brad Allan Weeks as President and David J. Swanberg as Chief Operating Officer, effective September 1, 2025, with their appointments disclosed on September 15, 2025. Weeks previously served as the company’s Business Development Manager and has a background in medical devices and biotechnology, while Swanberg brings over 35 years of experience in radiochemical processing, medical isotope production, and nuclear technologies.
Under his employment agreement running through December 31, 2027, Weeks will receive a base salary of $192,000 per year plus a $3,000 monthly grant in common stock, issued at the end of each fiscal quarter based on the closing share price, along with customary benefits and expense reimbursement. Swanberg’s consulting agreement runs through December 31, 2028 and provides $12,000 per month in consulting fees plus a $3,000 monthly grant in common stock on the same quarterly pricing basis, with standard confidentiality, non‑competition, and non‑solicitation provisions for both executives.
Vivos Inc. reported that its Board of Directors approved the creation of Vivos Scientific India LLP, a wholly owned legal entity based in India. This new subsidiary is intended to establish a manufacturing center, expand the company’s human therapies, and pursue commercialization of those therapies in the Indian market.
The company also plans to use Vivos Scientific India to generate additional human clinical trial data to support its process with the U.S. Food and Drug Administration. This step reflects a strategic focus on both international expansion and building a stronger evidence base for regulatory review.